Vascular Medicine

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
23:40

Houston Methodist DeBakey Heart and Vascular Center

Antithrombotic Therapies for PAD: How Effective Are Aspirin, Ticagrelor, Clopidogrel, Rivaroxaban and Cilostazol?

FEATURING Mark Creager
  • 308 views
  • March 24, 2021
22:34

Houston Methodist DeBakey Heart and Vascular Center

Antithrombotic Medication Management: How Long Is the Anticoagulation Gap for Patients on Warfarin and NOACs Undergoing Surgery? Is There a Way to Shorten the Gap?

FEATURING Geoffrey Barnes
  • 281 views
  • March 24, 2021
  • 2
08:11

Houston Methodist DeBakey Heart and Vascular Center

Broadening the Anticoagulation Clinic Role: How Efficient Is Aspirin for Primary Cardiovascular Prevention?

FEATURING Geoffrey Barnes
  • 570 views
  • March 24, 2021
  • 3
11:59

Houston Methodist DeBakey Heart and Vascular Center

Antithrombotic Medication Management: How to Dose DOAC and Prevent Adverse Events?

FEATURING Geoffrey Barnes
  • 263 views
  • March 24, 2021
  • 2
18:46

ASPC 2020 Virtual Summit on CVD Prevention

How Can We Prevent the Majority of CV Events? What Are the Milion Hearts Priorities?

FEATURING Laurence Sperling
  • 349 views
  • March 17, 2021
  • 2
28:45

ASPC 2020 Virtual Summit on CVD Prevention

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention With a Long-Term apoB Model? What Are the Benefits/Value of apoB? Why There Is apoB Resistance in the US vs. Europe?

FEATURING Allan Sniderman
  • 334 views
  • March 16, 2021
  • 5
28:23

ASPC 2020 Virtual Summit on CVD Prevention

New Insights Into Assessing Risk for Hispanic Patients: Why it Is Important to Discuss Risk Factors in Hispanics?

FEATURING Ileana Pina
  • 11 views
  • March 12, 2021
16:33

ASPC 2020 Virtual Summit on CVD Prevention

Menopause and Its Impact on Women's CVD Health: How to Assess Risk Factors? Can Hormone Theraphy Reduce CVD Risk?

FEATURING Erin Michos
  • 484 views
  • March 12, 2021
  • 2
16:05

ASPC 2020 Virtual Summit on CVD Prevention

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can Rosuvastatin + Candesartan + HCTZ Reduce CV Events?

FEATURING Keith Ferdinand
  • 164 views
  • March 12, 2021
  • 1
28:02

ASPC 2020 Virtual Summit on CVD Prevention

CVD Prevention for Women: What Are the Unique/Predominant Risk Factors in Women? Can Gender-Specific Management Improve ASCVD Outcomes?

FEATURING Nanette Wenger
  • 17 views
  • March 12, 2021
12:00

Mount Sinai Endovascular Fellows Course

Should You Treat Superficial Venous Reflux in Patients Who Previously Had DVT? When to Transfer from DOACs Therapy to Endovascular and Surgical?

FEATURING Vishal Kapur, Sungyup Pablo Kim, Karthik Gujja, Ajit Rao, Prakash Krishnan, Daniel Han
  • 30 views
  • February 18, 2021
06:37

37th Annual Advances in Heart Disease

Results of the COMPASS and VOYAGER PAD Trials: Is Rivaroxaban in Combination with Aspirin More Effective than Aspirin Alone for Secondary Cardiovascular Prevention in Patients with PAD?

FEATURING Mark Creager
  • 840 views
  • February 11, 2021
  • 1
35:24

37th Annual Advances in Heart Disease

ICU Management for COVID 19 Patients: What Are the Anticoagulation Strategies? What Therapies to Use for ARDS?

FEATURING Antonio Gomez, Priscilla Hsue
  • 177 views
  • February 5, 2021
  • 2
39:29

37th Annual Advances in Heart Disease

Contemporary Approach for Managing PAD: What Are the Guideline Recommended Therapies? What Is the Efficacy of Statin Therapy, PCSK9 Inhibitors, Antiplatelet Agents and Anticoagulants?

FEATURING Mark Creager, Binh An Phan
  • 257 views
  • February 4, 2021
  • 2
35:53

37th Annual Advances in Heart Disease

Evaluation of Cryptogenic Strokes: How to Diagnose Them? Should You Use Antiplatelet Agents as First-line Antithrombotic Therapy?

FEATURING Claude Hemphill, Binh An Phan
  • 541 views
  • February 4, 2021
  • 1
06:48

Cardiometabolic Health Congress (CMHC)

Cardiometabolic Medicine: What Are the Trends in Mortality, Risk & Blood Pressure Control?

FEATURING Keith Ferdinand
  • 348 views
  • January 15, 2021
07:20

Cardiometabolic Health Congress (CMHC)

Cardiometabolic Medicine: Does SGLT2i Improve HFrEF Symptoms, QOL, Reduce the Risk of Hospitalization and CV Mortality? Why Cardiologist Must Intervene in T2D?

FEATURING Keith Ferdinand
  • 103 views
  • January 15, 2021
  • 1
11:39

Mount Sinai Endovascular Fellows Course

Catheter-Based Interventions for Acute Pulmonary Embolism: What Are the Benefits and Risks?

FEATURING Jay Giri
  • 3,214 views
  • January 5, 2021
  • 19
14:53

William Peacock

MERCURY-PE Trial: Does the Outpatient Treatment with Rivaroxaban Decrease Hospitalization Caused by Bleeding and/or VTE Events?

  • 442 views
  • January 5, 2021
  • 6
19:15

Samuel Berkman

Update on DVT in COVID-19: Why Should We Consider Post Hospital Discharge Prophylaxis?

  • 888 views
  • December 28, 2020
  • 2
18:23

Cardiometabolic Health Congress (CMHC)

Insights From the COMPASS Trial: Management of PAD in Patients With Cardiometabolic Disease

FEATURING Deepak Bhatt
  • 146 views
  • December 18, 2020
22:50

Cardiometabolic Health Congress (CMHC)

PAD treatment for Patients With ALI, Polyvascular and Cardiometabolic Disease: How Effective Are Vorapaxar, Ticagrelor and Rivaroxaban?

FEATURING Marc Bonaca
  • 114 views
  • December 18, 2020
12:11

Cardiometabolic Health Congress (CMHC)

69 y/o Woman With LHC for NSTEMI & 76 y/o Woman With Life-Limiting Claudication: What Is the Optimal Management Strategy?

FEATURING Manesh Patel
  • 7 views
  • December 18, 2020
07:20

Cardiometabolic Health Congress (CMHC)

Panel Discussion on Preventing Adverse Cardiovascular and Limb Events in Cardiometabolic Patients with PAD: Recent Trials and Advances

FEATURING Deepak Bhatt, Marc Bonaca, Manesh Patel
  • 39 views
  • December 18, 2020
49:06

Gore Medical

Patient Selection for PFO Closure

FEATURING Jason Day
  • 662 views
  • December 16, 2020
  • 5

All Topics: